Sequential Afatinib and Osimertinib in Patients with Mutation-positive Non-small-cell Lung Cancer: Updated Analysis of the Observational GioTag Study

Overview

Journal Future Oncol

Specialty Oncology

Date 2019 Aug 3

PMID 31370698

Citations 39

Authors

Maximilian J Hochmair

Alessandro Morabito

Desiree Hao

Cheng-Ta Yang

Ross A Soo

James C-H Yang

Rasim Gucalp

Balazs Halmos

Lara Wang

Angela Marten

Tanja Cufer

Affiliations

Soon will be listed here.

Abstract

Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. NCT03370770.

Citing Articles

Osimertinib afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an exon 19 deletion or exon 21 L858R mutation.

Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B J Thorac Dis. 2023; 15(11):6115-6125.

PMID: 38090314 PMC: 10713299. DOI: 10.21037/jtd-23-686.

Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.

Ma W, Sheng Z, Niu Y, Yan B, Chen Y, Yang H Heliyon. 2023; 9(11):e20955.

PMID: 37920491 PMC: 10618502. DOI: 10.1016/j.heliyon.2023.e20955.

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.

Hsu P, Huang C, Lin Y, Lee S, Chiu L, Wu C Front Oncol. 2023; 13:1249106.

PMID: 37854677 PMC: 10579797. DOI: 10.3389/fonc.2023.1249106.

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.

Bian D, Sun L, Hu J, Duan L, Xia H, Zhu X Nat Commun. 2023; 14(1):4655.

PMID: 37537219 PMC: 10400609. DOI: 10.1038/s41467-023-40349-z.

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.

Pretelli G, Claudia Spagnolo C, Ciappina G, Santarpia M, Pasello G Int J Mol Sci. 2023; 24(10).

PMID: 37240224 PMC: 10218597. DOI: 10.3390/ijms24108878.